Crinetics

The drugmaker is paying up for a new growth engine. Is the price disciplined?

Crinetics stock nearly doubled Tuesday after Vertex Pharmaceuticals pledged $10 billion to buy the endocrinology-focused biotech company.

Q4

Jacqui Kirby Chief Corporate Affairs Officer Ask a person living with an endocrine condition where advocacy happens. They usually won't point to a headline or a Congressional hearing. Instead, they'll often point to a series of everyday experiences: the a

Fabian SchmidtVice President, Head of Medical Affairs - Europe Acromegaly presents a significant challenge for patients and the clinicians who care for them. The road to diagnosis is frequently prolonged, with symptoms that develop gradually and are commo

Key PointsThe biotech unveiled its third-quarter results.

Tom BeveridgeGlobal Product Lead, Paltusotine for Carcinoid Syndrome For individuals living with carcinoid syndrome (CS), a condition caused by neuroendocrine tumors (NETs), severe symptoms such as flushing, diarrhea and abdominal pain can significantly d

Isabel KalofonosChief Commercial Officer, Crinetics Pharmaceuticals For years, people living with acromegaly have navigated a care landscape that has remained largely unchanged. Often marked by a large treatment burden, managing treatment for the disease

Stephanie KallayDirector of Patient Advocacy Partners in Progress: How Patient Insights Drive Innovation At Crinetics, our mission has always been clear: to build the premier endocrine company that consistently pioneers new therapeutics to help patients b

Dr. Alan KrasnerChief Endocrinologist If you are living with acromegaly, you've likely heard your healthcare provider talk about "IGF-1" during your appointments. But what exactly is IGF-1, and why is it so important to understanding and managing your con